Doctor and Patient
Neurodegenerative Diseases and Dementia

Pathology leading to continues neuronal death 

Neurons are the fundamental building blocks of our central nervous system including the brain. They carry information throughout the human body via chemical and electrical signals and help to coordinate all the necessary functions of life. Neurons are different from other tissues are they are devoid of regeneration capacity. This means that “neurons you are born with is what you have to make last a lifetime”.

Neurodegenerative diseases are pathophysiological situations that lead to the death of neuronal cells. The most common and early symptom of neurodegenerative disease is the loss of memory and learning capacity. This condition is commonly known as Dementia and is considered as hallmark conditions for Alzheimer disease. However, it is also observed in Parkinson and Huntington’s disease. Other less common neurodegenerative disease leads to physical impairment.

In 2007, according to the Hospital Authority of Hong Kong, the prevalence rates of dementia was estimated to be at 5%-8% among persons aged over 65, and at 20%-30% among those aged over 80. About 35% of the Hong Kong population is at high risk of developing neurodegenerative disease.

Early Diagnosis can be the Solution 

Early detection is only way to prevent disease progression 

Sadly, noticeable symptoms of neurodegenerative disease are observed only after a significant loss of neuronal density. As neurons do not have regeneration capacity, it is considered “too late” when the first symptoms are observed.

Reports suggest that if pre-symptomatic and strategic interventions targeted at the specific neurodegenerative disease are made. A significant reduction in the progress and/or complete recovery of patients can be achieved in the majority of patients. The intervention methods can be an optimized battery of lifestyle and behavioral changes along with controlled use of preventive medication. The interventions can be of several kinds.

Together, Alzheimer’s, Parkinson, and Multiple Sclerosis constitute above 90% of all neurodegenerative disorders. Therefore, based on the already published clinical intervention studies. We have developed specific and targeted intervention strategies for Alzheimer’s, Parkinson, and Multiple Sclerosis.

 

Intervention therapies can be beneficial only if the diagnosis of these conditions is made at an asymptomatic stage.

Enjoying the View
2lfm-amyloid-beta(1 40).png
Blood Biomarkers in Blood

Sadly, noticeable symptoms of neurodegenerative disease are observed only after a significant loss of neuronal density. As neurons do not have regeneration capacity, it is considered “too late” when the first symptoms are observed.

Reports suggest that if pre-symptomatic and strategic interventions targeted at the specific neurodegenerative disease are made. A significant reduction in the progress and/or complete recovery of patients can be achieved in the majority of patients. The intervention methods can be an optimized battery of lifestyle and behavioral changes along with controlled use of preventive medication. The interventions can be of several kinds.

Together, Alzheimer’s, Parkinson, and Multiple Sclerosis constitute above 90% of all neurodegenerative disorders. Therefore, based on the already published clinical intervention studies. We have developed specific and targeted intervention strategies for Alzheimer’s, Parkinson, and Multiple Sclerosis.

 

Intervention therapies can be beneficial only if the diagnosis of these conditions is made at an asymptomatic stage.

ASSAY SERVICES

AlzheimersAwarenessRibbon.jpg

Alzheimers Disease 

Contributes to 75% of totall Dementia cases. Close to 50 million people are effected by Dementia.  Total cost of disease raised to  US $1 trillion  in 2018.

Parkinson Disease.jpg

Parkinsons Disease 

Globally Parkinson Disease affects 6.2 million people and resulted in about 117,400 deaths in 2015. Life expectancy post-diagnosis is between 7 -15 years 

multiple-sclerosis-ribbon-vectorjpg.jpg

Multiple Sclerosis 

Most common inflammatory neurological disease in young adults. Globallly, about 2 million Multiple Sclerosis patients were present in 2016.

Senior Physiotherapy

INTERVENTION THERAPY

Once neurodegeneration is diagnosed before the symptoms are observed. An intervention therapy can drastically improve the life quality of the patient by delaying or inhibiting pathological progression.

WHY IS INTERVENTION THERAPY BETTER?

Neurons lack regeneration capacity

It is known that neuronal cells are unable to regenerate. Therefore, symptomatic neurodegeneration is irreversible.

No effective cure

Although, several medical drugs are available for the treatment of neurodegenerative disorders yet none is considered effective.

 

Does not solely depend on drugs

Compound based therapeutics are known to cause side effects. Lifestyle interventions if effective are considered superior.

WE CAN PROVIDE INDIVIDUALIZED INTERVENTION THERAPY STEPS

ADDITIONAL SERVICES

Anatomical Model

KIDNEY DISEASE

Drug and Syringe

AUTOIMMUNE

Patient on Scale

OBESITY-DIABETES

Foot Muscles Model

INFLAMMATION

Blood Test

LIVER DISEASE

DRUG DISCOVERY COMPANIES

Identification of novel drug efficacy using brain scan technology to identify disease progression is expansive. Blood-based prognostic biomarkers will reduce the net cost of clinical research.

CLINICAL RESEARCH CENTERS

Identification of novel drug efficacy using brain scan technology to identify disease progression is expansive. Blood-based prognostic biomarkers will reduce the net cost of clinical research.

CLIINCAL DIAGNOSTIC CENTERS

Individuals identified at high risk of neurodegenerative disorders may conduct annual checkups for asymptomatic biomarkers to ensure early identification and better treatment.     

Individuals identified at high risk of neurodegenerative disorders may conduct annual checkups for asymptomatic biomarkers to ensure early identification and better treatment.     

PHYSICAL EXAMINATION CLINICS

White Structure

SUBMIT SAMPLES

to our office at

HKSTP

©2019 by ImmunoDiagnostics Limited.